文献速递药物相互作用抗栓抗凝管理

Sonidegib对安非他酮和华法林药代动力学的影响

The effect of sonidegib (LDE225) on the pharmacokinetics of bupropion and warfarin in patients with advanced solid tumours.
PubMed 文献 · Br J Clin Pharmacol · 2020-08-20

这项多中心开放标签研究在晚期实体瘤患者中评估sonidegib 800 mg每日一次对CYP2C9探针华法林和CYP2B6探针安非他酮药代动力学的影响。结果显示,sonidegib对华法林药效学和安非他酮药代动力学均无临床显著影响。

要点

  • Sonidegib 800 mg每日一次不影响华法林(CYP2C9探针)的药代动力学或药效学。
  • Sonidegib 800 mg每日一次不影响安非他酮(CYP2B6探针)的药代动力学。
  • Sonidegib 800 mg的安全性特征与200 mg相似,且不受单剂探针药物影响。

核心结论

  • Sonidegib 800 mg每日一次(高于FDA批准剂量)未影响华法林的药代动力学或药效学,也未影响安非他酮的药代动力学。

研究设计与样本

  • 多中心、开放标签研究,在晚期实体瘤患者中评估sonidegib对探针药物药代动力学的影响。
  • 队列1患者在第1天(导入期)和sonidegib治疗第2周期第22天(C2D22)接受单剂华法林15 mg。
  • 队列2患者在第1天(导入期)和C2D22接受单剂安非他酮75 mg。
  • 两队列均在导入期后开始sonidegib 800 mg每日一次口服,28天为一周期。

主要发现

  • (S)-华法林:AUCinf几何均值比[90%CI]为1.15 [1.07, 1.24],Cmax为0.88 [0.81, 0.97](联用sonidegib vs 不联用)。
  • (R)-华法林:AUCinf几何均值比为1.10 [0.98, 1.24],Cmax为0.93 [0.87, 1.0](联用sonidegib vs 不联用)。
  • 安非他酮:AUCinf几何均值比为1.10 [0.99, 1.23],Cmax为1.16 [0.95, 1.42](联用sonidegib vs 不联用)。

临床怎么用

  • 临床使用sonidegib 800 mg每日一次时,预计不会对华法林或安非他酮的暴露产生临床显著影响。
  • Sonidegib 800 mg的安全性特征与200 mg相似,且不受单剂华法林或安非他酮影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: We evaluated the potential effect of sonidegib at an oral dose of 800 mg once daily (QD) on the pharmacokinetics (PK) of the probe drugs warfarin (CYP2C9) and bupropion (CYP2B6). METHODS: This was a multicentre, open-label study to evaluate the effect of sonidegib on the PK of the probe drugs warfarin and bupropion in patients with advanced solid tumours. Cohort 1 patients received a single warfarin 15-mg dose on Day 1 of the run-in period and on Cycle 2 Day 22 (C2D22) of sonidegib administration. Cohort 2 patients received a single bupropion 75-mg dose on Day 1 of run-in period and on C2D22 of sonidegib administration. Sonidegib 800 mg QD oral dosing began on Cycle 1 Day 1 of a 28-day cycle after the run-in period in both cohorts. RESULTS: The geometric means ratios [90% confidence interval] for (S)-warfarin with and without sonidegib were: area under the concentration-time curve from time 0 to infinity (AUCinf ) 1.15 [1.07, 1.24] and maximum plasma concentration (Cmax ) 0.88 [0.81, 0.97]; and for (R)-warfarin were: AUCinf 1.10 [0.98, 1.24] and Cmax 0.93 [0.87, 1.0]. The geometric means ratios [90% confidence interval] of bupropion with and without sonidegib were: AUCinf 1.10 [0.99, 1.23] and Cmax 1.16 [0.95, 1.42]. Sonidegib 800 mg had a safety profile that was similar to that of lower dose sonidegib 200 mg and was unaffected by single doses of the probe drugs. CONCLUSIONS: Sonidegib dosed orally at 800 mg QD (higher than the Food and Drug Administration-approved dose) did not impact the PK or pharmacodynamics of warfarin (CYP2C9 probe substrate) or the PK of bupropion (CYP2B6 probe substrate).

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Pooler DB, Ness DB, Sarantopoulos J, et al. The effect of sonidegib (LDE225) on the pharmacokinetics of bupropion and warfarin in patients with advanced solid tumours. Br J Clin Pharmacol. 2020. PMID: 32736411. doi:10.1111/bcp.14508

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。